Quantification of Renal Sympathetic Vasomotion as a Novel End Point for Renal Denervation

Peter Ricci Pellegrino,Irving H Zucker,Yiannis S Chatzizisis,Han-Jun Wang,Alicia M Schiller,Irving H. Zucker,Yiannis S. Chatzizisis,Alicia M. Schiller
DOI: https://doi.org/10.1161/hypertensionaha.120.15325
IF: 9.8968
2020-09-16
Hypertension
Abstract:Download figure Download PowerPoint Renal sympathetic denervation, a potentially revolutionary interventional treatment for hypertension, faces an existential problem due to the inability to confirm successful ablation of the targeted renal sympathetic nerves. Based on the observation that renal sympathetic nerve activity exerts rhythmic, baroreflex-driven, and vasoconstrictive control of the renal vasculature, we developed a novel technique for identifying rhythmic sympathetic vascular control using a time-varying, 2-component Windkessel model of the renal circulation. This technology was tested in 2 different animal models of renal denervation; 10 rabbits underwent chronic, surgical renal denervation, and 9 pigs underwent acute, functional renal denervation via intrathecal administration of ropivacaine. Both methods of renal denervation reduced negative admittance gain, negative phase shift renal vascular control at known sympathetic vasomotor frequencies, consistent with a reduction in vasoconstrictive, baroreflex-driven renal sympathetic vasomotion. Classic measures like mean renal blood flow and mean renal vascular resistance were not significantly affected in either model of renal denervation. Renal sympathetic vasomotion monitoring could provide intraprocedural feedback for interventionists performing renal denervation and serve more broadly as a platform technology for the evaluation and treatment of diseases affecting the sympathetic nervous system.
peripheral vascular disease
What problem does this paper attempt to address?